logo
  • Home
  • Company
    • Management
    • Board of Directors
    • Governance
    • Medical and Scientific Advisory Board
  • Investors
    • Overview
    • News / Events
    • Shareholder Calls / Presentations
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • News & Media
    • Press Releases
    • Articles
    • Reports
    • Media
    • Photo Gallery
  • Contact
    • Social Media Community Guidelines

All SEC Filings

Navigation Toggle Navigation
  • Overview
  • News / Events
  • Shareholder Calls / Presentations
  • Company Information
  • Financial Information
  • Stock Data
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Corporate Governance
  • Quick Links
  • Email Alerts
  • Tear Sheet
  • Contacts
  • RSS News Feed
Filter Filings:
Date Form Description Docs XBRL Pages
11/08/21 S-3 Registration statement for specified transactions by certain issuers
Related Documents
EX-5.1
EX-23.1
HTML PDF 33
11/04/21 SC 13D Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities HTML PDF 14
09/14/21 10-Q Quarterly report pursuant to Section 13 or 15(d)
Related Documents
EX-31.1
EX-31.2
EX-32.1
EX-32.2
HTML PDF XBRL Viewer XLS XBRL Files 25
09/10/21 8-K Current report filing
Related Documents
EX-99.1
HTML PDF XBRL Viewer XLS XBRL Files 27
09/03/21 3 Initial statement of beneficial ownership of securities HTML PDF 2
09/01/21 D Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(a)(5) under the Act. HTML PDF 6
08/31/21 3 Initial statement of beneficial ownership of securities HTML PDF 2
08/31/21 3 Initial statement of beneficial ownership of securities HTML PDF 2
08/31/21 3 Initial statement of beneficial ownership of securities HTML PDF 2
08/30/21 SC 13G Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions HTML PDF 13
RSS
  • << Previous
  • 1...
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • ...43
  • Next >>

Contact Us

PharmaCyte Biotech, Inc.
3960 Howard Hughes Parkway, Suite 500
Las Vegas, Nevada 89169
Office Number: 917.595.2850
Facsimile Number: 917.595.2851
Email: info@PharmaCyte.com

Latest News

  • PharmaCyte Biotech, Inc. Announces Closing of $7 Million Financing August 20, 2025
  • PharmaCyte Biotech, Inc. Announces $7 Million Capital Raise Led by Existing Investors August 18, 2025